Evaluating a software tool for diagnosing CMV infection in pregnant women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the MyCMV 'expert' tool, a decision-making algorithm designed to assist health professionals in interpreting serological results for cytomegalovirus (CMV) infections during pregnancy. The tool aims to streamline the diagnosis process, which can be complex and often leads to delays in treatment. By providing clearer interpretations of CMV serology and PCR results, the study seeks to improve the timely administration of secondary prevention measures, such as valaciclovir, to protect the fetus. The study is observational and involves pregnant women who have undergone CMV serology testing at designated hospitals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pregnant woman
* And for whom a CMV serology including the search for CMV IgG and IgM antibodies is prescribed at the Necker-Enfants Malades or Paul Brousse hospital or CHU Limoges
* And with positive anti-CMV IgM or in the grey zone of the technique
* And for whom the date of start of pregnancy is known
* And who does not object to the use of their data in the context of this research

Exclusion Criteria: NA

Where it's running

• CHU de Limoges
  Limoges, France Recruiting
• Hôpital Necker-Enfants Malades
  Paris, France Recruiting
• Hôpital Paul Brousse
  Villejuif, France Recruiting

Study contacts

• Principal investigator: Jacques Fourgeaud, Pharma.D., PhD — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Jacques Dr Fourgeaud, Pharma.D., PhD
• Email: jacques.fourgeaud@aphp.fr
• Phone: 0033144495611

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CMV-specific T cells after CMV reactivation in adults after HSCT

  This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07688759

• Biomarkers linked to congenital CMV using newborn blood spots

  Researchers will test protein and RNA markers in dried blood spots from newborns to see if they can identify congenital CMV sequelae early.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT07635368

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

• Family-donor viral CTLs plus standard care vs standard care alone for refractory ADV or CMV infection after stem cell transplant

  This study tests whether using family-donor virus-specific CTLs in addition to usual treatment helps children, teens, and young adults with hard-to-treat CMV or adenovirus infections after a stem cell transplant.

  Recruiting Phase 3 New York Medical College · Valhalla, New York and 1 other locations · NCT07225972

• CMV-specific immunoglobulin to prevent CMV problems in children getting allogeneic stem cell transplants

  Doctors will try giving CMV-specific immunoglobulin to children having allogeneic stem cell transplants to prevent CMV reactivation and related transplant complications.

  Recruiting University of Pisa · Trieste · NCT07013370

• R-MVST cell therapy for viral infections in children and young adults

  This will try giving rapidly generated virus-specific T cells (R-MVST) to children and young adults whose weakened immune systems have recurrent or treatment-resistant infections with EBV, CMV, adenovirus, or BK virus.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06926894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.